Companion Diagnostics Market

Global Companion Diagnostics Market Size, Share, Development, Growth and Demand Forecast to 2023

Delivery : 24-72 Working Hours
Report Code: LS10044
Available Format:
Category : Biotechnology

Chapter 1. Research Background

1.1. Research Objectives

1.2. Market Definition

1.3. Research Scope

1.3.1. Market Segmentation by Indication

1.3.2. Market Segmentation by Technology

1.3.3. Market Segmentation by End User

1.3.4. Market Segmentation by Geography

1.3.5. Analysis Period

1.3.6. Market Data Reporting Unit

1.4. Key Stakeholders

Chapter 2. Research Methodology

2.1. Secondary Research

2.2. Primary Research

2.2.1. Breakdown of Primary Research Respondents By region By industry participants By company type

2.3. Market Size Estimation

2.4. Market Breakdown and Data Triangulation

2.5. Assumptions for the Study

Chapter 3. Executive Summary

Chapter 4. Introduction

4.1. Market Segmentation

4.1.1. Overview by Indication Breast cancer Lung cancer Colorectal cancer Gastric cancer Melanoma Other

4.1.2. Overview by Technology Immunohistochemistry (IHC) In situ hybridization (ISH) Polymerase chain reaction (PCR) Others

4.1.3. Overview by End User Pharmaceutical companies Reference labs Others

4.2. Market Dynamics

4.2.1. Trends

4.2.2. Drivers Impact analysis of drivers on market forecast

4.2.3. Restraints Impact analysis of restraints on market forecast

4.2.4. Opportunities

4.3. Porter’s Five Forces Analysis

Chapter 5. Market Size and Forecast by Indication

5.1. Breast Cancer

5.2. Lung Cancer

5.3. Colorectal Cancer

5.4. Gastric Cancer

5.5. Melanoma

5.6. Others

Chapter 6. Market Size and Forecast by Technology

6.1. Immunohistochemistry (IHC)

6.2. In situ hybridization (ISH)

6.3. Polymerase Chain Reaction (PCR)

6.4. Others

Chapter 7. Market Size and Forecast by End User

7.1. Pharmaceutical Companies

7.2. Reference Labs

7.3. Others

Chapter 8. Market Size and Forecast by Geography

8.1. North America Companion Diagnostics Market

8.1.1. By Indication

8.1.2. By Technology

8.1.3. By End User

8.1.4. By Country – U.S. and Canada

8.2. Europe Companion Diagnostics Market

8.2.1. By Indication

8.2.2. By Technology

8.2.3. By End User

8.2.4. By Country – Germany, France, U.K. and Rest of Europe

8.3. Asia-Pacific Companion Diagnostics Market

8.3.1. By Indication

8.3.2. By Technology

8.3.3. By End User

8.3.4. By Country – China, India, Japan and Rest of Asia-Pacific

8.4. Latin America Companion Diagnostics Market

8.4.1. By Indication

8.4.2. By Technology

8.4.3. By End User

8.4.4. By Country – Brazil, Mexico and Rest of Latin America

8.5. Middle East & Africa Companion Diagnostics Market

8.5.1. By Indication

8.5.2. By Technology

8.5.3. By End User

Chapter 9. Competitive Landscape

9.1. Competitive Analysis of Key Players

9.2. Global Strategic Developments

Chapter 10. Company Profiles

10.1. Abbott Laboratories, Inc.

10.1.1. Business Overview

10.1.2. Product and Service Offerings

10.1.3. Key Financial Summary

10.1.4. Strategic Growth Plan

10.2. Beckman Coulter, Inc.

10.2.1. Business Overview

10.2.2. Product and Service Offerings

10.2.3. Key Financial Summary

10.2.4. Strategic Growth Plan

10.3. BioGenex Laboratories Inc.

10.3.1. Business Overview

10.3.2. Product and Service Offerings

10.3.3. Key Financial Summary

10.3.4. Strategic Growth Plan

10.4. Agilent Technologies, Inc.

10.4.1. Business Overview

10.4.2. Product and Service Offerings

10.4.3. Key Financial Summary

10.4.4. Strategic Growth Plan

10.5. bioMérieux SA

10.5.1. Business Overview

10.5.2. Product and Service Offerings

10.5.3. Key Financial Summary

10.5.4. Strategic Growth Plan

10.6. Danaher Corporation

10.6.1. Business Overview

10.6.2. Product and Service Offerings

10.6.3. Key Financial Summary

10.6.4. Strategic Growth Plan

10.7. General Electric Company

10.7.1. Business Overview

10.7.2. Product and Service Offerings

10.7.3. Key Financial Summary

10.7.4. Strategic Growth Plan

10.8. Myriad Genetics, Inc.

10.8.1. Business Overview

10.8.2. Product and Service Offerings

10.8.3. Key Financial Summary

10.8.4. Strategic Growth Plan

10.9. Qiagen N.V.

10.9.1. Business Overview

10.9.2. Product and Service Offerings

10.9.3. Key Financial Summary

10.9.4. Strategic Growth Plan

10.10. F. Hoffmann-La Roche AG

10.10.1. Business Overview

10.10.2. Product and Service Offerings

10.10.3. Key Financial Summary

10.10.4. Strategic Growth Plan

*Note: Key financial summary and strategic growth plan will be provided on best effort basis and is subject to availability during primary and secondary research

Chapter 11. Appendix

11.1. Abbreviations

Place An Order

Single User License

The report will be delivered in PDF format without printing rights. It is recommended for a single user.

USD 5100
Group License

The report will be delivered in PDF format along with the printing rights. It is recommended for up to five users.

USD 6100
Enterprise License

The report will be delivered in PDF format along with printing rights and detailed Excel sheet. It is recommended for organizations where multiple people would like to access the report from multiple locations.

USD 9100

Pre-Purchase Enquiry